Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility is currently unavailable.

Kiyomi Mashima, Ph.D., M.D.

Title
Institution
Department
Address
Phone

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Mashima K, Oh I, Fujiwara K, Izawa J, Takayama N, Nakano H, Kawasaki Y, Minakata D, Yamasaki R, Morita K, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Fujiwara SI, Ohno N, Kanda Y. Comparison of alemtuzumab, anti-thymocyte globulin, and post-transplant cyclophosphamide for graft-versus-host disease and graft-versus-leukemia in murine models. PLoS One. 2021; 16(1):e0245232. PMID: 33428661.
    Citations:    Fields:    
  2. Inagaki T, Fujiwara K, Shinohara Y, Azuma M, Yamazaki R, Mashima K, Sakamoto A, Yashiro T, Ohno N. Perivascular macrophages produce type I collagen around cerebral small vessels under prolonged hypertension in rats. Histochem Cell Biol. 2021 Apr; 155(4):503-512. PMID: 33398434.
    Citations: 1     Fields:    
  3. Morita K, Fujiwara SI, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Nagayama T, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Ohmine K, Kanda Y. Identification of endoscopic factors that predict poor responses to steroids in patients with gastrointestinal acute graft-versus-host disease. Bone Marrow Transplant. 2021 Apr; 56(4):963-967. PMID: 33139868.
    Citations:    Fields:    
  4. Nagayama T, Fujiwara SI, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Morita K, Kawasaki Y, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y. Steep neutrophil recovery following unrelated bone marrow transplantation is a major risk factor for the development of acute graft-vs-host disease-a retrospective study. Transpl Int. 2020 12; 33(12):1723-1731. PMID: 32939883.
    Citations: 1     Fields:    
  5. Nagayama T, Ashizawa M, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Morita K, Kawasaki Y, Yamamoto C, Fujiwara SI, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y. Factors that predict delayed platelet recovery after autologous stem cell transplantation for lymphoma or myeloma. Ann Hematol. 2020 Dec; 99(12):2893-2901. PMID: 32572522.
    Citations:    Fields:    Translation:HumansCells
  6. Ikeda T, Fujiwara SI, Nakajima H, Kawaguchi SI, Toda Y, Ito S, Ochi S, Nagayama T, Mashima K, Umino K, Minakata D, Nakano H, Morita K, Yamasaki R, Kawasaki Y, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y. Impact of prednisolone dosage in the CHOP regimen for follicular lymphoma: a retrospective study. Int J Hematol. 2020 Sep; 112(3):369-376. PMID: 32529585.
    Citations:    Fields:    Translation:Humans
  7. Mashima K, Azuma M, Fujiwara K, Inagaki T, Oh I, Ikeda T, Umino K, Nakano H, Morita K, Sato K, Minakata D, Yamasaki R, Ashizawa M, Yamamoto C, Fujiwara SI, Hatano K, Ohmine K, Muroi K, Ohno N, Kanda Y. Differential Localization and Invasion of Tumor Cells in Mouse Models of Human and Murine Leukemias. Acta Histochem Cytochem. 2020 Jun 26; 53(3):43-53. PMID: 32624629.
    Citations: 1     
  8. Ito S, Fujiwara SI, Ikeda T, Toda Y, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y. Evaluation of thrombotic events in patients with immune thrombocytopenia. Ann Hematol. 2020 Jan; 99(1):49-55. PMID: 31853702.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  9. Umino K, Hatano K, Ochi SI, Genda H, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Nagayama T, Mashima K, Minakata D, Nakano H, Yamasaki R, Morita K, Yamamoto C, Ashizawa M, Sato K, Oh I, Fujiwara SI, Ohmine K, Muroi K, Kanda Y. The impact of overweight on renal toxicity in patients treated with dexamethasone, high-dose cytarabine, and cisplatin. Int J Hematol. 2020 Mar; 111(3):396-400. PMID: 31728828.
    Citations:    Fields:    Translation:Humans
  10. Yamamoto C, Nakashima H, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Mashima K, Nagayama T, Umino K, Minakata D, Nakano H, Morita K, Yamasaki R, Sugimoto M, Ishihara Y, Ashizawa M, Hatano K, Sato K, Oh I, Fujiwara SI, Ueda M, Ohmine K, Muroi K, Kanda Y. Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation. Blood Adv. 2019 11 12; 3(21):3266-3277. PMID: 31698458.
    Citations: 5     Fields:    Translation:Humans
  11. Morita K, Ashizawa M, Toda Y, Ikeda T, Kawaguchi SI, Ito S, Ochi SI, Nagayama T, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Yamamoto C, Hatano K, Fujiwara SI, Sato K, Oh I, Ohmine K, Muroi K, Matsumoto K, Kanda Y. Salvage Chemotherapy Followed by Autologous Stem-Cell Transplantation Using Targeted Busulfan for Refractory Diffuse Large B-Cell Lymphoma With Dialysis-Dependent End-Stage Renal Disease. Clin Lymphoma Myeloma Leuk. 2020 02; 20(2):e92-e96. PMID: 31787588.
    Citations:    Fields:    
  12. Kawasaki Y, Sato K, Nakano H, Hayakawa H, Izawa J, Takayama N, Mashima K, Oh I, Minakata D, Yamasaki R, Morita K, Ashizawa M, Yamamoto C, Hatano K, Fujiwara SI, Ohmine K, Muroi K, Ito R, Hayakawa M, Ohmori T, Kanda Y. Alloreactive T Cells Display a Distinct Chemokine Profile in Response to Conditioning in Xenogeneic GVHD Models. Transplantation. 2019 09; 103(9):1834-1843. PMID: 31461746.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  13. Minakata D, Fujiwara SI, Hayakawa J, Nakasone H, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Nagayama T, Mashima K, Umino K, Nakano H, Yamasaki R, Morita K, Kawasaki Y, Sugimoto M, Ishihara Y, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Ohmori T, Kanda Y. Comparison of Danaparoid Sodium and Synthetic Protease Inhibitors for the Treatment of Disseminated Intravascular Coagulation Associated with Hematological Malignancies: A Retrospective Analysis. Acta Haematol. 2020; 143(3):250-259. PMID: 31461700.
    Citations: 3     Fields:    Translation:Humans
  14. Umino K, Fujiwara SI, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Nagayama T, Mashima K, Minakata D, Nakano H, Yamasaki R, Morita K, Kawasaki Y, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y. Predictive value of soluble interlukin-2 receptor level at diagnosis on the outcome for patients with classical Hodgkin lymphoma treated with ABVD with or without radiotherapy. Ann Hematol. 2019 Sep; 98(9):2121-2129. PMID: 31240469.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  15. Umino K, Fujiwara SI, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Nagayama T, Mashima K, Minakata D, Nakano H, Yamasaki R, Morita K, Kawasaki Y, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y. Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2019 08; 60(8):1926-1933. PMID: 30947577.
    Citations: 1     Fields:    Translation:Humans
  16. Morita K, Fujiwara SI, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Nagayama T, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Ashizawa K, Yamamoto Y, Oshiro H, Kanda Y. TAFRO Syndrome with an Anterior Mediastinal Mass and Lethal Autoantibody-Mediated Thrombocytopenia: An Autopsy Case Report. Acta Haematol. 2019; 141(3):158-163. PMID: 30799408.
    Citations:    Fields:    Translation:Humans
  17. Kawasaki Y, Kimura SI, Nakano H, Mashima K, Shirato Y, Kawaguchi SI, Toda Y, Ochi SI, Nagayama T, Minakata D, Yamasaki R, Morita K, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Fujiwara SI, Ohmine K, Kako S, Muroi K, Kanda Y. Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index. Int J Hematol. 2019 Apr; 109(4):470-476. PMID: 30684252.
    Citations:    Fields:    Translation:Humans
  18. Minakata D, Fujiwara SI, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Nagayama T, Mashima K, Umino K, Nakano H, Yamasaki R, Morita K, Kawasaki Y, Sugimoto M, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Ohmori T, Kanda Y. Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies. Int J Hematol. 2019 Feb; 109(2):141-146. PMID: 30536180.
    Citations: 7     Fields:    Translation:Humans
  19. Mashima K, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Nagayama T, Umino K, Minakata D, Nakano H, Yamasaki R, Morita K, Kawasaki Y, Sugimoto M, Ishihara Y, Ashizawa M, Yamamoto C, Fujiwara SI, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y. Comparison of blast percentage calculated based on bone marrow all nucleated cells and non-erythroid cells in myelodysplastic syndromes with erythroid hyperplasia. Ann Hematol. 2019 May; 98(5):1127-1133. PMID: 30474718.
    Citations:    Fields:    Translation:HumansCellsCTClinical Trials
  20. Mashima K, Ikeda T, Toda Y, Ito S, Umino K, Minakata D, Nakano H, Morita K, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Fujiwara S, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y. Associations between the peripheral blood Wilms tumor gene 1 level and both bone marrow blast cells and the prognosis in patients with myelodysplastic syndrome. Leuk Lymphoma. 2019 03; 60(3):703-710. PMID: 30188227.
    Citations:    Fields:    Translation:HumansCells
  21. Mashima K, Oh I, Ikeda T, Toda Y, Ito S, Umino K, Minakata D, Nakano H, Morita K, Yamasaki R, Kawasaki Y, Sugimoto M, Yamamoto C, Ashizawa M, Fujiwara SI, Hatano K, Sato K, Omine K, Muroi K, Kanda Y. Role of Sequential Monitoring of WT1 Gene Expression in Patients With Acute Myeloid Leukemia for the Early Detection of Leukemia Relapse. Clin Lymphoma Myeloma Leuk. 2018 12; 18(12):e521-e527. PMID: 30181104.
    Citations:    Fields:    Translation:Humans
  22. Ito S, Ashizawa M, Sasaki R, Ikeda T, Toda Y, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Yamamoto C, Fujiwara SI, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Suzuki J, Hatakeyama S, Morisawa Y, Yamada T, Kanda Y. False-positive elevation of 1,3-beta-D-glucan caused by continuous administration of penicillin G. J Infect Chemother. 2018 Oct; 24(10):812-814. PMID: 30006248.
    Citations:    Fields:    Translation:HumansCells
  23. Kawasaki Y, Sato K, Hayakawa H, Takayama N, Nakano H, Ito R, Mashima K, Oh I, Minakata D, Yamasaki R, Morita K, Ashizawa M, Yamamoto C, Hatano K, Fujiwara SI, Ohmine K, Muroi K, Kanda Y. Comprehensive Analysis of the Activation and Proliferation Kinetics and Effector Functions of Human Lymphocytes, and Antigen Presentation Capacity of Antigen-Presenting Cells in Xenogeneic Graft-Versus-Host Disease. Biol Blood Marrow Transplant. 2018 08; 24(8):1563-1574. PMID: 29678638.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  24. Umino K, Fujiwara SI, Ikeda T, Toda Y, Ito S, Mashima K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y. Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement. Hematology. 2018 Sep; 23(8):470-477. PMID: 29486661.
    Citations: 2     Fields:    Translation:Humans
  25. Minakata D, Sato K, Ikeda T, Toda Y, Ito S, Mashima K, Umino K, Nakano H, Yamasaki R, Morita K, Kawasaki Y, Sugimoto M, Yamamoto C, Ashizawa M, Hatano K, Oh I, Fujiwara SI, Ohmine K, Kawata H, Muroi K, Miura I, Kanda Y. A leukemic double-hit follicular lymphoma associated with a complex variant translocation, t(8;14;18)(q24;q32;q21), involving BCL2, MYC, and IGH. Cancer Genet. 2018 01; 220:44-48. PMID: 29310838.
    Citations: 1     Fields:    Translation:HumansCells
  26. Fujiwara SI, Shirato Y, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Nagayama T, Mashima K, Umino K, Minakata D, Nakano H, Morita K, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y. Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia. Int J Hematol. 2018 Jun; 107(6):712-715. PMID: 29185155.
    Citations: 3     Fields:    Translation:Humans
  27. Minakata D, Fujiwara SI, Ikeda T, Toda Y, Ito S, Mashima K, Umino K, Nakano H, Yamasaki R, Morita K, Kawasaki Y, Sugimoto M, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y. Relationship between white blood cell count elevation and clinical response after G-CSF priming chemotherapy for acute myeloid leukemia. Int J Hematol. 2017 Sep; 106(3):411-417. PMID: 28508228.
    Citations: 1     Fields:    Translation:Humans
  28. Umino K, Fujiwara SI, Ikeda T, Toda Y, Ito S, Mashima K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y. Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP. Hematology. 2017 Oct; 22(9):521-526. PMID: 28413914.
    Citations: 1     Fields:    Translation:Humans
  29. Mashima K, Yano S, Yokoyama H, Saito T, Machishima T, Shimada T, Yahagi Y, Takahara S, Sugiyama K, Ogasawara Y, Minami J, Kamiyama Y, Katsube A, Suzuki K, Ohshima S, Yamada H, Usui N, Aiba K. Epstein-Barr Virus-associated Lymphoproliferative Disorder with Encephalitis Following Anti-thymocyte Globulin for Aplastic Anemia Resolved with Rituximab Therapy: A Case Report and Literature Review. Intern Med. 2017; 56(6):701-706. PMID: 28321074.
    Citations: 3     Fields:    Translation:HumansCells
  30. Ito S, Fujiwara SI, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y. Development of acute myeloid leukemia in patients with untreated chronic lymphocytic leukemia. Ann Hematol. 2017 May; 96(5):719-724. PMID: 28144729.
    Citations: 2     Fields:    Translation:Humans
  31. Sugimoto M, Ito S, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Ashizawa M, Yamamoto C, Fujiwara S, Okazuka K, Hatano K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kako S, Kanda Y. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan. Ann Hematol. 2016 Sep; 95(9):1513-9. PMID: 27365141.
    Citations: 5     Fields:    Translation:Humans
  32. Umino K, Fujiwara SI, Ito S, Mashima K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y. Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma. Leuk Lymphoma. 2017 02; 58(2):316-323. PMID: 27267694.
    Citations:    Fields:    Translation:Humans
  33. Yamamoto C, Ito S, Mashima K, Umino K, Minakata D, Yamasaki R, Kawasaki Y, Sugimoto M, Nakano H, Ashizawa M, Okazuka K, Hatano K, Sato K, Oh I, Fujiwara S, Ohmine K, Suzuki T, Muroi K, Kanda Y. Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia. Leuk Lymphoma. 2016 11; 57(11):2541-7. PMID: 26917050.
    Citations:    Fields:    Translation:Humans
  34. Minakata D, Fujiwara S, Ito S, Mashima K, Umino K, Nakano H, Kawasaki Y, Sugimoto M, Yamasaki R, Yamamoto C, Ashizawa M, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis. Leuk Res. 2016 Mar; 42:82-7. PMID: 26790727.
    Citations: 5     Fields:    Translation:Humans
  35. Nakano H, Fujiwara SI, Ito S, Mashima K, Umino K, Minakata D, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y. The prognostic significance of rapid peripheral blood blast clearance during the initial course of induction chemotherapy in young patients with de novo acute myeloid leukemia. Hematol Oncol. 2017 Sep; 35(3):357-364. PMID: 26639319.
    Citations:    Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Mashima's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (185)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.